Your browser doesn't support javascript.
Glycyrrhizin: An old weapon against a novel coronavirus.
Chrzanowski, Julian; Chrzanowska, Alicja; Grabon, Wojciech.
  • Chrzanowski J; Chair and Department of Biochemistry, Medical University of Warsaw, Banacha 1, Warsaw, Poland.
  • Chrzanowska A; Chair and Department of Biochemistry, Medical University of Warsaw, Banacha 1, Warsaw, Poland.
  • Grabon W; Chair and Department of Biochemistry, Medical University of Warsaw, Banacha 1, Warsaw, Poland.
Phytother Res ; 35(2): 629-636, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1098919
ABSTRACT
Currently, over 100 countries are fighting against a common enemy, the severe acute respiratory syndrome coronavirus (SARS-CoV)-2, which causes COVID-19. This has created a demand for a substance whose effectiveness has already been demonstrated in a similar scenario. Glycyrrhizin (GZ) is a promising agent against SARS-CoV-2 as its antiviral activity against SARS-CoV has already been confirmed. It is worthwhile to extrapolate from its proven therapeutic effects as there is a high similarity in the structure and genome of SARS-CoV and SARS-CoV-2. There are many possible mechanisms through which GZ acts against viruses increasing nitrous oxide production in macrophages, affecting transcription factors and cellular signalling pathways, directly altering the viral lipid-bilayer membrane, and binding to the ACE2 receptor. In this review, we discuss the possible use of GZ in the COVID-19 setting, where topical administration appears to be promising, with the nasal and oral cavity notably being the potent location in terms of viral load. The most recently published papers on the distribution of ACE2 in the human body and documented binding of GZ to this receptor, as well as its antiviral activity, suggest that GZ can be used as a therapeutic for COVID-19 and as a preventive agent against SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Chemoprevention / Glycyrrhizic Acid / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study Limits: Humans Language: English Journal: Phytother Res Journal subject: Complementary Therapies Year: 2021 Document Type: Article Affiliation country: Ptr.6852

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Chemoprevention / Glycyrrhizic Acid / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Observational study Limits: Humans Language: English Journal: Phytother Res Journal subject: Complementary Therapies Year: 2021 Document Type: Article Affiliation country: Ptr.6852